Acute toxicological evaluation of AT-533 and AT-533 gel in Sprague-Dawley rats.
AT-533
AT-533 gel
Acute toxicity
Sprague-Dawley rats
Journal
BMC pharmacology & toxicology
ISSN: 2050-6511
Titre abrégé: BMC Pharmacol Toxicol
Pays: England
ID NLM: 101590449
Informations de publication
Date de publication:
13 10 2023
13 10 2023
Historique:
received:
20
04
2023
accepted:
10
10
2023
medline:
23
10
2023
pubmed:
14
10
2023
entrez:
14
10
2023
Statut:
epublish
Résumé
AT-533 is a novel heat shock protein 90 inhibitor that exerting anti-inflammatory, antiviral, and antitumor efficacy. Furthermore, the gel made of AT-533 as raw material named AT-533 gel has the function of repairing keratitis and dermatitis caused by herpes virus infection. However, the acute safety evaluation of AT-533 and AT-533 gel has not been conducted. Herein, we performed acute toxicological studies of AT-533 and AT-533 gel in Sprague-Dawley rats. Fifteen-day acute toxicity study of AT-533 was conducted in both male and female Sprague-Dawley rats at doses of 5, 50, 250 and 500 mg/kg and AT-533 gel at 5 g/kg in the study. During experiment, food consumption and mortality were observed and body weight, hematology, serum biochemistry and histopathological assessment of rats were carried out. No abnormal changes were observed in rats percutaneously treated with AT-533 at 5 mg/kg and 50 mg/kg and AT-533 gel. However, loss of appetite and body weight, adverse reactions, toxicologically relevant alterations in hematology and biochemistry were found in rats percutaneously treated with AT-533 at 250 mg/kg and 500 mg/kg during 15-day acute dermic toxicity study. The aforementioned results suggested that the LD
Sections du résumé
BACKGROUND
AT-533 is a novel heat shock protein 90 inhibitor that exerting anti-inflammatory, antiviral, and antitumor efficacy. Furthermore, the gel made of AT-533 as raw material named AT-533 gel has the function of repairing keratitis and dermatitis caused by herpes virus infection. However, the acute safety evaluation of AT-533 and AT-533 gel has not been conducted.
METHODS AND RESULTS
Herein, we performed acute toxicological studies of AT-533 and AT-533 gel in Sprague-Dawley rats. Fifteen-day acute toxicity study of AT-533 was conducted in both male and female Sprague-Dawley rats at doses of 5, 50, 250 and 500 mg/kg and AT-533 gel at 5 g/kg in the study. During experiment, food consumption and mortality were observed and body weight, hematology, serum biochemistry and histopathological assessment of rats were carried out. No abnormal changes were observed in rats percutaneously treated with AT-533 at 5 mg/kg and 50 mg/kg and AT-533 gel. However, loss of appetite and body weight, adverse reactions, toxicologically relevant alterations in hematology and biochemistry were found in rats percutaneously treated with AT-533 at 250 mg/kg and 500 mg/kg during 15-day acute dermic toxicity study.
CONCLUSIONS
The aforementioned results suggested that the LD
Identifiants
pubmed: 37833798
doi: 10.1186/s40360-023-00696-5
pii: 10.1186/s40360-023-00696-5
pmc: PMC10576390
doi:
Substances chimiques
AT-533
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
54Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Clin Cancer Res. 2008 Jan 1;14(1):240-8
pubmed: 18172276
J Biochem. 2018 Dec 1;164(6):397-406
pubmed: 30107464
Bioorg Med Chem Lett. 2012 Jul 15;22(14):4703-6
pubmed: 22704890
Biochem Biophys Res Commun. 2014 Jul 18;450(1):73-80
pubmed: 24879994
Mech Ageing Dev. 2021 Dec;200:111587
pubmed: 34656616
Biochem Pharmacol. 2020 Feb;172:113771
pubmed: 31863779
Eur J Drug Metab Pharmacokinet. 2022 May;47(3):345-352
pubmed: 35137361
Recent Pat Anticancer Drug Discov. 2012 Sep;7(3):313-36
pubmed: 22338602
Mol Med. 2018 Dec 22;24(1):65
pubmed: 30577726
Regul Toxicol Pharmacol. 2022 Aug;133:105188
pubmed: 35636684
Nat Rev Cancer. 2005 Oct;5(10):761-72
pubmed: 16175177
Cancer. 2003 Sep 1;98(5):970-7
pubmed: 12942564
EJNMMI Radiopharm Chem. 2023 Jan 30;8(1):2
pubmed: 36715827
Arch Virol. 2017 Nov;162(11):3269-3282
pubmed: 28780632
J Med Chem. 2009 Jul 23;52(14):4288-305
pubmed: 19552433
Front Microbiol. 2022 Jan 10;12:799890
pubmed: 35082770
Viruses. 2020 May 09;12(5):
pubmed: 32397571
Bioorg Med Chem Lett. 2011 Mar 15;21(6):1675-7
pubmed: 21334891
Pharmaceutics. 2021 Aug 17;13(8):
pubmed: 34452244
Eur J Pharmacol. 2017 Jan 5;794:52-60
pubmed: 27871911
BMC Complement Med Ther. 2020 Jan 13;20(1):2
pubmed: 32020865
Onco Targets Ther. 2019 Feb 11;12:1119-1128
pubmed: 30809093
Front Oncol. 2019 Dec 18;9:1447
pubmed: 31921692
Toxicol Appl Pharmacol. 2021 Apr 15;417:115464
pubmed: 33636197
Cell Stress Chaperones. 2016 Mar;21(2):213-8
pubmed: 26786410
Front Microbiol. 2022 Feb 03;12:797279
pubmed: 35185822
Exp Ther Med. 2021 Jun;21(6):632
pubmed: 33968163
Biochem Pharmacol. 2019 Aug;166:82-92
pubmed: 31071330
Cell Stress Chaperones. 1996 Jun;1(2):97-8
pubmed: 9222594